Comparative Pharmacology
Head-to-head clinical analysis: K 8 versus KLOR CON M10.
Peer-Reviewed Evidence
Head-to-head clinical analysis: K 8 versus KLOR CON M10.
K+8 vs KLOR-CON M10
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Potassium ion replenishment; corrects hypokalemia by increasing extracellular potassium concentration, restoring membrane potential and cardiac conduction.
Potassium chloride dissociates to release potassium ions which are essential for maintaining cellular membrane potential, nerve impulse transmission, muscle contraction, and acid-base balance. Replacement of potassium deficits prevents or corrects hypokalemia.
40-80 mEq intravenously per day, infusion rate not exceeding 10 mEq/hour; or 20-40 mEq orally 2-4 times daily.
For potassium depletion: 10 mEq orally three to four times daily, with maximum single dose of 20 mEq and total daily dose up to 100 mEq. Dosage must be individualized based on serum potassium levels and clinical response.
None Documented
None Documented
Terminal elimination half-life ~2-4 hours (shorter with valproate coadministration, prolonged with renal impairment).
Not applicable; potassium is an electrolyte with continuous homeostatic regulation. The plasma half-life of potassium is approximately 2-3 hours, but this is not clinically meaningful as elimination is dependent on renal function and total body stores.
Primarily renal: >90% excreted unchanged by kidneys. Minor fecal (<5%) and negligible biliary elimination.
Renal: >90% of potassium intake is excreted by the kidneys, primarily via distal tubular secretion.
Category C
Category C
Potassium Supplement
Potassium Supplement